BMJ  2006;333 (12 August), doi:10.1136/bmj.333.7563.0-b

Spironolactone is associated with upper GI events

The risk of gastroduodenal ulcers or upper gastrointestinal bleeding is significantly increased in patients taking spironolactone. A population based case-control study by Verhamme and colleagues (p 330) matched 523 cases of gastroduodenal ulcer or upper gastrointestinal bleeding to 5230 controls from the same Dutch primary care database and found that current use of spironolactone was associated with a 2.7-fold increased risk of a gastrointestinal event. The association increased proportionally with dose and was most pronounced when spironolactone was combined with ulcerogenic drugs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Spironolactone and risk of upper gastrointestinal events: population based case-control study

Katia Verhamme, Georgio Mosis, Jeanne Dieleman, Bruno Stricker, and Miriam Sturkenboom
BMJ 2006 333: 330. [Abstract] [Full Text] [PDF]